Identification of a unique nsaid, fluoro-loxoprofen with gastroprotective activity

Biochemical Pharmacology

Volumn 84, Issue 11, 2012, Pages 1470-1481

  Suemasu, Shintaro ^a,b   Yamakawa, Naoki ^a,b   Ishihara, Tomoaki ^a   Asano, Teita ^a   Tahara, Kayoko ^a   Tanaka, Ken Ichiro ^a,b   Matsui, Hirofumi ^c   Okamoto, Yoshinari ^b   Otsuka, Masami ^b   Takeuchi, Koji ^d   Suzuki, Hidekazu ^a   Mizushima, Tohru ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Gastrointestinal complications; Mucus; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; FLUORO LOXOPROFEN; INDOMETACIN; LOXOPROFEN; MUCIN 1; MUCIN 5AC; MUCIN 6; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; IN VITRO STUDY; INTRACELLULAR SIGNALING; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; STOMACH ACID SECRETION; STOMACH CONTENT; STOMACH LESION; STOMACH PH; STOMACH PROTECTION; ULCEROGENESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; CULTURE MEDIA; IN SITU NICK-END LABELING; PHENYLPROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84868506260     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.09.016     Document Type: Article

References (53)

1. P. Holzer Neural emergency system in the stomach Gastroenterology 114 1998 823 839
2. T.A. Miller Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms Am J Physiol 245 1983 G601 G623
3. W.E. Smalley, W.A. Ray, J.R. Daugherty, and M.R. Griffin Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons Am J Epidemiol 141 1995 539 545
4. C.J. Hawkey Nonsteroidal anti-inflammatory drug gastropathy Gastroenterology 119 2000 521 535
5. L.M. Lichtenberger Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury. Topical injury revisited Biochem Pharmacol 61 2001 631 637
6. B.J. Whittle New dogmas or old Gut 52 2003 1379 1381
7. M. Gupta, and G.M. Eisen NSAIDs and the gastrointestinal tract Curr Gastroenterol Rep 11 2009 345 353
8. R.A. Levine, and E.H. Schwartzel Effect of indomethacin on basal and histamine stimulated human gastric acid secretion Gut 25 1984 718 722
9. M. Phillipson, M.E. Johansson, J. Henriksnas, J. Petersson, S.J. Gendler, and S. Sandler The gastric mucus layers: constituents and regulation of accumulation Am J Physiol Gastrointest Liver Physiol 295 2008 G806 G812
10. M. Ligumsky, E.M. Golanska, D.G. Hansen, and G.J. Kauffman Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat Gastroenterology 84 1983 756 761
11. M. Ligumsky, M. Sestieri, F. Karmeli, J. Zimmerman, E. Okon, and D. Rachmilewitz Rectal administration of nonsteroidal antiinflammatory drugs Effect on rat gastric ulcerogenicity and prostaglandin E2 synthesis Gastroenterology 1990 1245 1249
12. K. Tanaka, W. Tomisato, T. Hoshino, T. Ishihara, T. Namba, and M. Aburaya Involvement of Intracellular Ca2+ Levels in Nonsteroidal Anti-inflammatory Drug-induced Apoptosis J Biol Chem 280 2005 31059 31067
13. S. Tsutsumi, T. Gotoh, W. Tomisato, S. Mima, T. Hoshino, and H.J. Hwang Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis Cell Death Differ 11 2004 1009 1016
14. W. Tomisato, K. Tanaka, T. Katsu, H. Kakuta, K. Sasaki, and S. Tsutsumi Membrane permeabilization by non-steroidal anti-inflammatory drugs Biochem Biophys Res Commun 323 2004 1032 1039
15. W. Tomisato, S. Tsutsumi, K. Rokutan, T. Tsuchiya, and T. Mizushima NSAIDs induce both necrosis and apoptosis in guinea pig gastric mucosal cells in primary culture Am J Physiol Gastrointest Liver Physiol 281 2001 G1092 G1100
16. M. Aburaya, K. Tanaka, T. Hoshino, S. Tsutsumi, K. Suzuki, and M. Makise Heme oxygenase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs J Biol Chem 281 2006 33422 33432
17. S. Tsutsumi, T. Namba, K.I. Tanaka, Y. Arai, T. Ishihara, and M. Aburaya Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells Oncogene 25 2006 1018 1029
18. T. Namba, T. Hoshino, K. Tanaka, S. Tsutsumi, T. Ishihara, and S. Mima Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells Mol Pharmacol 71 2007 860 870
19. T. Ishihara, T. Hoshino, T. Namba, K. Tanaka, and T. Mizushima Involvement of up-regulation of PUMA in non-steroidal anti-inflammatory drug-induced apoptosis Biochem Biophys Res Commun 356 2007 711 717
20. W. Tomisato, S. Tsutsumi, T. Hoshino, H.J. Hwang, M. Mio, and T. Tsuchiya Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions Biochem Pharmacol 67 2004 575 585
21. J. Vane Towards a better aspirin Nature 367 1994 215 216
22. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, and A. Whelton Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 2000 1247 1255
23. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, V.R. Burgos, and B. Davis Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 2000 1520 1528 2 p following 8
24. G.A. FitzGerald, and C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433 442
25. D. Mukherjee, S.E. Nissen, and E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 286 2001 954 959
26. D. Mukherjee Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events Biochem Pharmacol 63 2002 817 821
27. B.F. McAdam, L.F. Catella, I.A. Mardini, S. Kapoor, J.A. Lawson, and G.A. FitzGerald Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci USA 96 1999 272 277
28. L.F. Catella, B. McAdam, B.W. Morrison, S. Kapoor, D. Kujubu, and L. Antes Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids J Pharmacol Exp Ther 289 1999 735 741
29. O. Belton, D. Byrne, D. Kearney, A. Leahy, and D.J. Fitzgerald Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis Circulation 102 2000 840 845
30. N. Yamakawa, S. Suemasu, A. Kimoto, Y. Arai, T. Ishihara, and K. Yokomizo Low direct cytotoxicity of loxoprofen on gastric mucosal cells Biol Pharm Bull 33 2010 398 403
31. E. Misaka, T. Yamaguchi, Y. Iizuka, K. Kamoshida, T. Kojima, and K. Kobayashi Anti-inflammatory, Analgesic and Antipyretic Activities of Sodium 2-[4-(2-oxocyclopentan-1-ylmethyl)phenyl] Propionate Dihydrate (CS-600)* Pharmacometrics 21 1981 753 771
32. S. Kawano, S. Tsuji, N. Hayashi, Y. Takei, K. Nagano, and H. Fusamoto Effects of loxoprofen sodium, a newly synthesized non-steroidal anti-inflammatory drug, and indomethacin on gastric mucosal haemodynamics in the human J Gastroenterol Hepatol 10 1995 81 85
33. M. Sugimoto, T. Kojima, M. Asami, Y. Iizuka, and K. Matsuda Inhibition of prostaglandin production in the inflammatory tissue by loxoprofen-Na, an anti-inflammatory prodrug Biochem Pharmacol 42 1991 2363 2368
34. N. Yamakawa, S. Suemasu, M. Matoyama, A. Kimoto, M. Takeda, and K. Tanaka Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl)methyl] phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low membrane permeabilizing and gastric lesion-producing activities J Med Chem 53 2010 7879 7882
35. K. Takeuchi, S. Ueki, and S. Okabe Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats Dig Dis Sci 31 1986 1114 1122
36. A. Tanaka, M. Matsumoto, Y. Hayashi, and K. Takeuchi Functional mechanism underlying cyclooxygenase-2 expression in rat small intestine following administration of indomethacin: relation to intestinal hypermotility J Gastroenterol Hepatol 20 2005 38 45
37. T. Asano, K. Tanaka, N. Yamakawa, H. Adachi, G. Sobue, and H. Goto HSP70 confers protection against indomethacin-induced lesions of the small intestine J Pharmacol Exp Ther 330 2009 458 467
38. L. Filaretova, A. Tanaka, T. Miyazawa, S. Kato, and K. Takeuchi Mechanisms by which endogenous glucocorticoid protects against indomethacin-induced gastric injury in rats Am J Physiol Gastrointest Liver Physiol 283 2002 G1082 G1089
39. M.L. Anson The estimation of pepsin, trypsin, papain, and cathepsin with hemoglobin J Gen Physiol 22 1938 79 89
40. J.P. Bolton, D. Palmer, and M.M. Cohen Stimulation of mucus and nonparietal cell secretion by the E2 prostaglandins Am J Dig Dis 23 1978 359 364
41. I. Kobayashi, S. Kawano, S. Tsuji, H. Matsui, A. Nakama, and H. Sawaoka RGM1, a cell line derived from normal gastric mucosa of rat In Vitro Cell Dev Biol Anim 32 1996 259 261
42. S. Ohara, T. Watanabe, and K. Hotta Comparative study of carbohydrate portion of gastrointestinal mucins using enzyme-linked lectin-binding assay (ELLA) Comp Biochem Physiol B: Biochem Mol Biol 116 1997 167 172
43. T. Fujii, Y. Takahashi, A. Ikari, M. Morii, Y. Tabuchi, and K. Tsukada Functional association between K + -Cl- cotransporter-4 and H+,K + -ATPase in the apical canalicular membrane of gastric parietal cells J Biol Chem 284 2009 619 629
44. T. Fujii, Y. Ohira, Y. Itomi, Y. Takahashi, S. Asano, and M. Morii Inhibition of P-type ATPases by [(dihydroindenyl)oxy]acetic acid (DIOA), a K+ -Cl- cotransporter inhibitor Eur J Pharmacol 560 2007 123 126
45. A. Yoda, and L.E. Hokin On the reversibility of binding of cardiotonic steroids to a partially purified (Na + K)-activated adenosinetriphosphatase from beef brain Biochem Biophys Res Commun 40 1970 880 886
46. S.S. Oner, A.I. Kaya, H.O. Onaran, G. Ozcan, and O. Ugur Beta2-Adrenoceptor, Gs and adenylate cyclase coupling in purified detergent-resistant, low density membrane fractions Eur J Pharmacol 630 2010 42 52
47. A. Ohnishi, C. Shimamoto, K. Katsu, S. Ito, Y. Imai, and T. Nakahari EP1 and EP4 receptors mediate exocytosis evoked by prostaglandin E(2) in guinea-pig antral mucous cells Exp Physiol 86 2001 451 460
48. R.A. Coleman, W.L. Smith, and S. Narumiya International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes Pharmacol Rev 46 1994 205 229
49. N. Yamakawa, S. Suemasu, H. Watanabe, K. Tahara, K.I. Tanaka, and Y. Okamoto Comparison of pharmacokinetics between loxoprofen and its derivative with lower ulcerogenic activity, fluoro-loxoprofen Drug Metab Pharmacokinet 2012
50. J.L. Goldstein, G.M. Eisen, B. Lewis, I.M. Gralnek, J. Aisenberg, and P. Bhadra Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy Aliment Pharmacol Ther 25 2007 1211 1222
51. L. Aabakken, B.A. Bjornbeth, R. Weberg, L. Viksmoen, S. Larsen, and M. Osnes NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum Aliment Pharmacol Ther 4 1990 295 303
52. S. Somasundaram, G. Sigthorsson, R.J. Simpson, J. Watts, M. Jacob, and I.A. Tavares Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat Aliment Pharmacol Ther 14 2000 639 650
53. J. Basivireddy, A. Vasudevan, M. Jacob, and K.A. Balasubramanian Indomethacin-induced mitochondrial dysfunction and oxidative stress in villus enterocytes Biochem Pharmacol 64 2002 339 349